WallStSmart

TotalEnergies SE ADR (TTE)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

TotalEnergies SE ADR generates 1419% more annual revenue ($182.34B vs $12.00B). VRTX leads profitability with a 32.9% profit margin vs 7.2%. TTE appears more attractively valued with a PEG of 0.77. VRTX earns a higher WallStSmart Score of 66/100 (B-).

TTE

Buy

55

out of 100

Grade: C-

Growth: 2.0Profit: 5.5Value: 7.0Quality: 5.0

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for TTE.

VRTXUndervalued (+56.2%)

Margin of Safety

+56.2%

Fair Value

$976.24

Current Price

$427.38

$548.86 discount

UndervaluedFair: $976.24Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TTE5 strengths · Avg: 8.4/10
Market CapQuality
$205.37B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.778/10

Growing faster than its price suggests

P/E RatioValuation
13.7x8/10

Attractively priced relative to earnings

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$6.53B8/10

Generating 6.5B in free cash flow

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$108.71B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

TTE3 concerns · Avg: 2.3/10
Profit MarginProfitability
7.2%3/10

7.2% margin — thin

Revenue GrowthGrowth
-2.5%2/10

Revenue declined 2.5%

EPS GrowthGrowth
-27.4%2/10

Earnings declined 27.4%

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.084/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : TTE

The strongest argument for TTE centers on Market Cap, PEG Ratio, P/E Ratio. PEG of 0.77 suggests the stock is reasonably priced for its growth.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : TTE

The primary concerns for TTE are Profit Margin, Revenue Growth, EPS Growth.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

TTE profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

VRTX carries more volatility with a beta of 0.37 — expect wider price swings.

VRTX is growing revenue faster at 9.5% — sustainability is the question.

TTE generates stronger free cash flow (6.5B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 55/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

TotalEnergies SE ADR

ENERGY · OIL & GAS INTEGRATED · USA

TotalEnergies SE is a global integrated oil and gas company. The company is headquartered in Paris, France.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?